Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

被引：0
|
作者：
Kozioff, M.
Sledge, G. W.
Benedetti, F. M.
Starr, A.
Wallace, J. A.
Stuart, M. J.
Gruver, D.
Miller, K.
机构：
[1] Ingalls Hosp, Harvey, IL USA
[2] Univ Chicago, Harvey, IL USA
[3] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[4] Genon Corp, Menlo Pk, CA USA
[5] Monroe Med Assoc, Harvey, IL USA
[6] Univ Chicago, St Marys Hosp, Monroe Med Assoc, Chicago, IL 60637 USA
[7] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2598
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer
    Kutomi, Goro
    Ohmura, Tousei
    Satomi, Fukino
    Maeda, Hideki
    Shima, Hiroaki
    Kameshima, Hidekazu
    Okazaki, Minoru
    Masuoka, Hideji
    Sasaki, Kenichi
    Hirata, Koichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (03) : 474 - 479
  • [32] Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Morris, P. G.
    Chang, J. C.
    Abbruzzi, A.
    Patil, S.
    Modi, S.
    Seidman, A. D.
    Sklarin, N. T.
    Norton, L.
    Hudis, C.
    Fornier, M. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Phase I evaluation of lapatinib (L) and epirubicin (E) in patients (pts) with anthracycline (anth)-naive metastatic breast cancer (MBC)
    O'Connor, R. A.
    Kennedy, M. J.
    McDermott, S. R.
    Tryfanopoulos, D.
    McCreery, C.
    Collins, D.
    Martynyuk, O.
    Gethins, R.
    Moulton, B.
    Crown, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+metastatic breast cancer (MBC)
    Jagiello-Gruszfeld, A.
    Tjulandin, Sergei S.
    Dobrovolskava, N.
    Manikhas, A.
    Pienkowski, T.
    Knott, A.
    DeSilvio, M.
    Oliva, C.
    CANCER RESEARCH, 2009, 69 (02) : 246S - 246S
  • [35] Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors.
    Chiorean, E. G.
    Matei, D.
    Younger, A.
    Funke, J. M.
    Waddell, M. J.
    Jones, D. R.
    Hahn, N. M.
    Perkins, S. M.
    Sandrasegaran, K.
    Sweeney, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Phase I/II study of sunitinib (SU) in combination with metronomic dosing of cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic breast cancer (MBC)
    Chien, A. J.
    Aicardi, J.
    Melisko, M. E.
    Goga, A.
    Moasser, M. M.
    Park, J. W.
    Munster, P. N.
    Rugo, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC)
    Schneeweiss, Andreas
    Aigner, Julia
    Smetanay, Katherina
    Schuetz, Florian
    Sohn, Christof
    Kriegsmann, Mark
    Jaeger, Dirk
    Zorn, Markus
    Bachinger, Andreas
    Sinn, Hans-Peter
    Marme, Frederik
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
    Dieras, V.
    Jassem, J.
    Dirix, L. Y.
    Guastalla, J. P.
    Bono, P.
    Hurvitz, S. A.
    Goncalves, A.
    Romieu, G.
    Limentani, S. A.
    Jerusalem, G. H. M.
    Lakshmaiah, K.
    Roche, H. H.
    Sanchez-Rovira, P.
    Pienkowski, T.
    Segui-Palmer, M. A.
    Li, A.
    Sun, Y.
    Pickett-Gies, C. A.
    Wildiers, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC)
    Isakoff, Steven J.
    Bendell, Johanna C.
    Cervantes, Andres
    Soria, Jean-Charles
    Molife, L. R.
    Sanabria-Bohorquez, Sandra M.
    Punnoose, Elizabeth A.
    Jia, Shidong
    Patel, Premal
    Saura, Cristina
    CANCER RESEARCH, 2015, 75
  • [40] Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients
    Guan, Z.
    Xu, B.
    DeSilvio, M.
    Newstat, B.
    Moore, Y.
    Makhson, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S345 - S345
12345